Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors

详细信息    查看全文

• 作者：Vera A. Machado^a ; ^b ; ^c ; Daniela Peixoto^a ; Raquel Costa^b ; ^c ; Hugo J.C. Froufe^d ; Ricardo C. Calhelha^a ; ^d ; Rui M.V. Abreu^d ; Isabel C.F.R. Ferreira^d ; Raquel Soares^b ; ^c ; Maria-Joã ; o R.P. Queiroz^a ; ^{mjrpq@quimica.uminho.pt" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Thienopyridinethioether 1 ; 3-diarylureas ; VEGFR-2 tyrosine kinase inhibitors ; Enzymatic assays ; Molecular docking ; HUVECs ; Antiangiogenesis assays ; Western blotting
• 刊名：Bioorganic & Medicinal Chemistry
• 出版年：2015
• 出版时间：1 October 2015
• 年：2015
• 卷：23
• 期：19
• 页码：6497-6509
• 全文大小：2326 K

文摘

The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a–4h, with the arylurea in the meta position to the thioether, showed the lowest IC₅₀ values in enzymatic assays (10–206 nM), the most potent compounds 4d–4h (IC₅₀ 10–28 nM) bearing hydrophobic groups (Me, F, CF₃ and Cl) in the terminal phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentrations. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited at 1.0 and 2.5 渭M for the most promising compounds. Altogether, these findings point to an antiangiogenic effect in HUVECs.